系统性硬化症中抗RNA聚合酶III抗体:系统综述与Meta分析中的患病率及临床关联
该系统综述与Meta分析纳入93项研究共23038例系统性硬化症患者,汇总抗RNA聚合酶III抗体总体血清阳性率为9%(95%CI:8-10),异质性高(I²=88%,P<0.001)。该抗体阳性与弥漫性皮肤亚型、关节表现、胃窦血管扩张症、心脏受累、硬皮病肾危象、间质性肺病及癌症显著相关。作者认为抗体阳性患者可能从上述严重并发症的适当筛查中获益。
要点
- 抗RNA聚合酶III抗体在系统性硬化症中的总体血清阳性率为9%(95%CI:8-10),研究间异质性高(I²=88%,P<0.001)。
- 抗体阳性与硬皮病肾危象关联最强(OR 7.82,95%CI:5.79-10.57),其次为胃窦血管扩张症(OR 2.70,95%CI:1.52-4.81)。
- 抗体阳性还与弥漫性皮肤亚型、关节表现、心脏受累、间质性肺病及癌症显著相关。
核心结论
- 抗RNA聚合酶III抗体在系统性硬化症中的总体血清阳性率为9%(95%CI:8-10),抗体阳性患者发生严重皮肤扩展和肾危象的风险更高,并与癌症、胃窦血管扩张症、心脏、关节受累及间质性肺病呈正相关。
- 作者认为抗RNA聚合酶III抗体阳性的系统性硬化症患者可能从这些潜在严重并发症的适当筛查中获益。
研究设计与样本
- 系统综述与Meta分析,检索Pubmed和Embase截至2024年6月的文献,纳入93项研究共23038例系统性硬化症患者,采用Meta分析评估抗体患病率及临床关联,存在异质性时行Meta回归寻找潜在协变量。
主要发现
- 抗RNA聚合酶III抗体总体血清阳性率为9%(95%CI:8-10),异质性高(I²=88%,P<0.001)。
- 抗体阳性与弥漫性皮肤亚型显著相关(OR 2.20,95%CI:1.91-2.53)。
- 抗体阳性与关节表现显著相关(OR 1.29,95%CI:1.01-1.66)。
- 抗体阳性与胃窦血管扩张症显著相关(OR 2.70,95%CI:1.52-4.81)。
- 抗体阳性与心脏受累显著相关(OR 1.93,95%CI:1.18-3.18)。
关键数值与推荐
- 抗RNA聚合酶III抗体阳性与硬皮病肾危象显著相关(OR 7.82,95%CI:5.79-10.57)。
- 抗RNA聚合酶III抗体阳性与间质性肺病显著相关(OR 1.10,95%CI:1.00-1.20)。
- 抗RNA聚合酶III抗体阳性与癌症显著相关(OR 1.86,95%CI:1.33-2.59)。
临床怎么用
- 作者认为抗RNA聚合酶III抗体阳性的系统性硬化症患者可能从针对严重皮肤扩展、肾危象、癌症、胃窦血管扩张症、心脏、关节受累及间质性肺病等潜在严重并发症的适当筛查中获益。
局限性
- 抗RNA聚合酶III抗体总体血清阳性率存在高度异质性(I²=88%,P<0.001)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Anti-RNA polymerase III antibodies (ARA) are frequent in systemic sclerosis (SSc). However, the reported prevalence is variable among studies and some clinical associations are debated. We aimed (i) to update the recent data on overall ARA prevalence in SSc and heterogeneity between centres; and (ii) to describe their clinical associations. METHODS: A systematic review of the literature available up to June 2024 was carried out in Pubmed and Embase. Meta-analyses were performed to assess the prevalence and clinical associations of ARA in SSc, combined with meta-regressions in case of heterogeneity to identify potential cofactors. RESULTS: Ninety-three studies corresponding to a total of 23 038 SSc patients were included in the meta-analysis. In this population, the overall seroprevalence of ARA was 9% (95% CI: 8-10) with a high degree of heterogeneity (I2 = 88%, P < 0.001). ARA positivity was significantly associated with diffuse cutaneous subset (OR: 2.20 [1.91-2.53]), joint manifestations (OR: 1.29 [1.01-1.66]), gastric antral vascular ectasia (GAVE) (OR: 2.70 [1.52-4.81]), heart involvement (OR: 1.93 [1.18-3.18]), scleroderma renal crisis (OR: 7.82 [5.79-10.57]), interstitial lung disease (ILD) (OR: 1.10 [1.00-1.20]) and cancer (OR: 1.86 [1.33-2.59]). CONCLUSION: This study provides an overall seroprevalence of ARA of 9% [8-10] and confirms that SSc patients with ARA are at higher risk of severe skin extension and renal crisis. It also highlights a positive association with cancer, GAVE, heart, joint involvement and ILD. ARA positive SSc patients could therefore benefit from an appropriate screening of these potentially severe complications.
引用
- Elhannani A, Martel ME, Collet A, et al. Anti-RNA polymerase III antibodies in systemic sclerosis: prevalence and clinical associations from a systematic review and meta-analysis. Rheumatology (Oxford). 2025. PMID: 40676730. doi:10.1093/rheumatology/keaf392
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。